A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A phase 1/2 trial of YL201 and Atezolizumab in small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07407933 by MediLink Therapeutics (Suzhou) Co., Ltd., with 118 participants planned, started 2026-03-31 and due to reach its primary completion in 2028-11. Interventions recorded: YL201 and Atezolizumab.
Similar pages
not linked directly; found by shared links- TrialA Study of YL201 in Patients With Advanced Solid Tumors
Shares YL201, Atezolizumab and the tag pipeline.
- TrialStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Shares Flatiron Health (Roche), Atezolizumab, Small-cell lung cancer and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Shares Flatiron Health (Roche) and the tag pipeline.